GHK-Cu accelerates irradiated fibroblast proliferation and boosts bFGF and VEGF output
Background
Radiation-induced wound healing impairment is a persistent clinical problem in patients treated for head and neck cancer, where ionizing radiation damages dermal fibroblasts and disrupts normal tissue repair. Irradiated fibroblasts show reduced proliferative capacity and impaired autocrine growth factor signaling, leaving post-radiation wounds prone to chronic non-healing. Standard wound care does not address the underlying fibroblast deficit or the suppression of angiogenic and mitogenic signaling. GHK-Cu (copper tripeptide glycyl-L-histidyl-L-lysine complexed with copper) is a naturally occurring peptide-metal complex under investigation as a promoter of fibroblast activity and growth factor expression, making it a candidate to partially restore radiation-damaged tissue biology.
Study Design
Primary human dermal fibroblast cell lines were established via explantation from intraoperative specimens of patients who had undergone radiation therapy for head and neck cancer. Both normal and irradiated fibroblasts were propagated in serum- and growth factor-free media to isolate autocrine effects. Treatment groups received GHK-Cu at 1 × 10⁻⁹ mol/L (1 nM); untreated cells served as controls. Primary endpoints were cell counts (population-doubling time) and autocrine production of bFGF, TGF-β1, and VEGF, measured under serum-free conditions.
Results
Both normal and irradiated fibroblasts survived and replicated in serum-free media, validating the model for isolated growth factor assessment. Population-doubling times of both normal and irradiated fibroblasts exposed to GHK-Cu were faster than those of non-treated controls. Critically, irradiated fibroblasts treated with GHK-Cu doubled at a rate that approximated the population-doubling time of untreated normal fibroblasts, partially reversing the radiation-induced proliferative deficit. GHK-Cu-treated irradiated fibroblasts produced significantly more bFGF and VEGF than untreated irradiated controls, with the effect observed early after GHK-Cu exposure. TGF-β1 production was measured but no significant differential result for that cytokine is reported in the abstract.
Irradiated fibroblasts treated with GHK-Cu doubled at a rate approximating that of untreated normal controls, and produced significantly more bFGF and VEGF early after exposure.
Key Findings
- GHK-Cu at 1 nM accelerated population-doubling in both normal and irradiated human dermal fibroblasts vs. untreated controls.
- Irradiated fibroblasts treated with GHK-Cu reached doubling times approximating untreated normal fibroblast controls.
- GHK-Cu-treated irradiated fibroblasts produced significantly more bFGF and VEGF than untreated irradiated controls early post-exposure.
- Irradiated fibroblasts survived and replicated in serum-free, growth factor-free media, validating the model.
- TGF-β1 was measured but no significant differential result for that cytokine is noted in the abstract.
Why It Matters
GHK-Cu's ability to partially normalize irradiated fibroblast proliferation and upregulate bFGF and VEGF output points toward a plausible topical or local application strategy for radiation-impaired wound healing — a population with very few effective options. Clinicians and researchers working in post-radiation reconstructive care now have in vitro mechanistic data supporting a rationale for GHK-Cu as a wound-bed preparation agent. For peptide users, the serum-free model confirms that the effects observed are genuinely autocrine and not confounded by exogenous growth factors, strengthening confidence in the signal. Translation from this cell-culture model to a clinical protocol will require dose-ranging, delivery-vehicle development, and in vivo validation, meaning practical protocols are still multiple research stages away.
TitrateLab articles covering GHK-Cu
Written by TitrateLab, separately from the study summarized above.
